Use of antiviral agents and other therapies for COVID-19
MAT Blaskovich, AD Verderosa - Seminars in Respiratory and …, 2023 - thieme-connect.com
The coronavirus disease 2019 (COVID-19) pandemic led to a remarkably rapid
development of a range of effective prophylactic vaccines, including new technologies that …
development of a range of effective prophylactic vaccines, including new technologies that …
A guide to COVID‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV‐2 infection
DK Brady, AR Gurijala, L Huang, AA Hussain… - The FEBS …, 2024 - Wiley Online Library
Antiviral therapies are integral in the fight against SARS‐CoV‐2 (ie severe acute respiratory
syndrome coronavirus 2), the causative agent of COVID‐19. Antiviral therapeutics can be …
syndrome coronavirus 2), the causative agent of COVID‐19. Antiviral therapeutics can be …
Report of the national institutes of health SARS-CoV-2 antiviral therapeutics summit
MD Hall, JM Anderson, A Anderson… - The Journal of …, 2021 - academic.oup.com
Abstract The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was
organized to provide an overview on the status and challenges in developing antiviral …
organized to provide an overview on the status and challenges in developing antiviral …
Antiviral drugs and vaccines
Humankind is adopting different countermeasures to control viral infections, including the
development of antiviral agents for treatments and vaccines as a prophylactic measure to …
development of antiviral agents for treatments and vaccines as a prophylactic measure to …
The need for antiviral drugs for pandemic coronaviruses from a global health perspective
Respiratory failure due to SARS-CoV-2 has caused widespread mortality, creating an urgent
need for effective treatments and a long-term need for antivirals for future emergent …
need for effective treatments and a long-term need for antivirals for future emergent …
[HTML][HTML] COVID-19 antiviral and treatment candidates: current status
E Españo, D Kim, J Kim, SK Park, JK Kim - Immune network, 2021 - ncbi.nlm.nih.gov
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 has severely impacted global health and economy …
respiratory syndrome coronavirus 2 has severely impacted global health and economy …
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
BY Arman, J Brun, ML Hill, N Zitzmann… - International Journal of …, 2023 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic has claimed over 7 million lives
worldwide, providing a stark reminder of the importance of pandemic preparedness. Due to …
worldwide, providing a stark reminder of the importance of pandemic preparedness. Due to …
Guidance for the pharmacological management of COVID-19 in the emergency setting
MH Temsah, M Al-Jelaify, ZA Memish - Expert opinion on …, 2022 - Taylor & Francis
Since the early days of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
pandemic, therapeutic trials into pharmacological management of coronavirus-2019 (COVID …
pandemic, therapeutic trials into pharmacological management of coronavirus-2019 (COVID …
Update on antiviral strategies against COVID-19: unmet needs and prospects
CH Liu, CH Lu, SH Wong, LT Lin - Frontiers in Immunology, 2021 - frontiersin.org
By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed
cases and 1.6 million related deaths around the world. However, only a few drugs have …
cases and 1.6 million related deaths around the world. However, only a few drugs have …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …